Stockscreener 앱 받기
36.71
1.55%
0.56
시간 외 거래:
37.44
0.73
+1.99%
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP) - Stock Titan
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock By Investing.com - Investing.com India
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP) - GuruFocus
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock - Investing.com
Rapport Therapeutics (RAPP) CDO sells small block of shares - Stock Titan
Risk Report: Is Rapport Therapeutics Inc gaining market shareEarnings Recap Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale - Stock Titan
Bond Watch: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Earnings Risk: What are Rapport Therapeutics Incs technical support levels2026 Spike Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
(RAPP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics to present epilepsy trial data at AAN By Investing.com - Investing.com South Africa
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - Sahm
Rapport Therapeutics to present epilepsy trial data at AAN - Investing.com
Rapport's new 8-week seizure data heads to a major neurology meeting - Stock Titan
Market Catalysts: Is Rapport Therapeutics Inc a good stock for dollar cost averaging2026 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Rapport Therapeutics COO Gault sells $281k in stock By Investing.com - Investing.com Canada
Rapport Therapeutics COO Gault sells $281k in stock - investing.com
Rapport Therapeutics Insider Sold Shares Worth $281,857, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) COO sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
10,000-share Rule 144 sale by RAPP (NASDAQ: RAPP) lists $278,400 value - Stock Titan
Patterns Watch: What is the cash position of Rapport Therapeutics IncMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Aug Ideas: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Will Rapport Therapeutics' RAP-219 Deliver A Pipeline-in-a-Product Story? - RTTNews
Rapport Therapeutics (NASDAQ:RAPP) Raised to “Strong-Buy” at Truist Financial - defenseworld.net
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k By Investing.com - Investing.com India
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $303,355, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) CDO sells 10,115 shares under 10b5-1 plan - Stock Titan
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
All Essential Information Regarding Rapport Therapeutics, Inc. (RAPP) Rating Raised to Buy - Bitget
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Truist Financial - MarketBeat
RAPP (NASDAQ: RAPP) insider sale reported: 2,840 common shares - Stock Titan
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily
RAPP SEC FilingsRapport Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RAPP Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
2.69%
0.25%
자본화:
|
볼륨(24시간):